Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin

Cancer

Volumn 118, Issue 10, 2012, Pages 2665-2673

  Ravandi, Farhad ^a   Patel, Keyur ^a   Luthra, Rajyalakshmi ^a   Faderl, Stefan ^a   Konopleva, Marina ^a   Kadia, Tapan ^a   Brandt, Mark ^a   Pierce, Sherry ^a   Kornblau, Steven ^a   Andreeff, Michael ^a   Wang, Xuemei ^a   Garcia Manero, Guillermo ^a   Cortes, Jorge ^a   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

AML; IDH; mutations; outcome; SNP

Indexed keywords

CYTARABINE; IDARUBICIN; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; ISOENZYME; SORAFENIB; TIPIFARNIB; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CHROMOSOME ABERRATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DIPLOIDY; DISEASE DURATION; DOSE RESPONSE; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; GENETIC ASSOCIATION; GENETIC CODE; GENOTYPE; HUMAN; ISOCITRATE DEHYDROGENASE 1 GENE; ISOCITRATE DEHYDROGENASE 2 GENE; KARYOTYPING; MAJOR CLINICAL STUDY; MALE; MOLECULAR MODEL; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GENE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; HUMANS; IDARUBICIN; ISOCITRATE DEHYDROGENASE; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS;

EID: 84860677744     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26580     Document Type: Article

References (34)

1. Haselbeck RJ, McAlister-Henn L,. Function and expression of yeast mitochondrial NAD- and NADP-specific isocitrate dehydrogenases. J Biol Chem. 1993; 268: 12116-12122.
2. Plaut GW, Cook M, Aogaichi T,. The subcellular location of isozymes of NADP-isocitrate dehydrogenase in tissues from pig, ox and rat. Biochim Biophys Acta. 1983; 760: 300-308.
3. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006; 314: 268-274.
4. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321: 1807-1812.
5. Bleeker FE, Lamba S, Leenstra S, et al. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat. 2009; 30: 7-11.
6. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009; 360: 765-773.
7. Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009; 118: 469-474.
8. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009; 462: 739-744.
9. Zhao S, Lin Y, Xu W, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science. 2009; 324: 261-265.
10. Reitman ZJ, Yan H,. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst. 2010; 102: 932-941.
11. Kang MR, Kim MS, Oh JE, et al. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer. 2009; 125: 353-355.
12. Park SW, Chung NG, Han JY, et al. Absence of IDH2 codon 172 mutation in common human cancers. Int J Cancer. 2009; 125: 2485-2486.
13. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009; 361: 1058-1066.
14. Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2010; 28: 2348-2355.
15. Paschka P, Schlenk RF, Gaidzik VI, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol. 2010; 28: 3636-3643.
16. Boissel N, Nibourel O, Renneville A, et al. Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group. J Clin Oncol. 2010; 28: 3717-3723.
17. Wagner K, Damm F, Gohring G, et al. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol. 2010; 28: 2356-2364.
18. Green CL, Evans CM, Hills RK, Burnett AK, Linch DC, Gale RE,. The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. Blood. 2010; 116: 2779-2782.
19. Abbas S, Lugthart S, Kavelaars FG, et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood. 2010; 116: 2122-2126.
20. Ravandi F, Cortes JE, Jones D, et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol. 2010; 28: 1856-1862.
21. Jabbour E, Kantarjian H, Ravandi F, et al. A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2011; 117: 1236-1244.
22. Garcia-Manero G, Tambaro FP, Bekele N, et al. Final report of a phase II trial of vorinostat, idarubicin and cytarabine in previously untreated acute myelogenous leukemia (AML) or high risk myelodysplastic syndrome (MDS). Blood. 2010; 116.
23. Kiyoi H, Naoe T,. FLT3 in human hematologic malignancies. Leuk Lymphoma. 2002; 43: 1541-1547.
24. Dang L, Jin S, Su SM,. IDH mutations in glioma and acute myeloid leukemia. Trends Mol Med. 2010; 16: 387-397.
25. Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol. 2009; 27: 5743-5750.
26. Pardanani A, Patnaik MM, Lasho TL, et al. Recurrent IDH mutations in high-risk myelodysplastic syndrome or acute myeloid leukemia with isolated del(5q). Leukemia. 2010; 24: 1370-1372.
27. Thol F, Weissinger EM, Krauter J, et al. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica. 2010; 95: 1668-1674.
28. Green A, Beer P,. Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med. 2010; 362: 369-370.
29. Chou WC, Hou HA, Chen CY, et al. Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood. 2010; 115: 2749-2754.
30. Thol F, Damm F, Wagner K, et al. Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood. 2010; 116: 614-616.
31. Bleeker FE, Atai NA, Lamba S, et al. The prognostic IDH1(R132) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol. 2010; 119: 487-494.
32. Gross S, Cairns RA, Minden MD, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med. 2010; 207: 339-344.
33. Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010; 17: 225-234.
34. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010; 18: 553-567.